Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Thakkar

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Expert Review of Respiratory Medicine|September 26, 2018
Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practiceMelanie Lavender, Karen Sw Chia, Nathan Dwyer, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Rheumatology (Oxford, England)|October 16, 2012
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Nicole Goh, Tamera Corte, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Pulmonary Circulation|June 10, 2026
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX StudyMandana Nikpour, Alicia Calderone, Susanna M Proudman, et al.
BMJ Open|December 10, 2016
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolAlicia Calderone, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|June 14, 2012
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyVivek Thakkar, Wendy M Stevens, David Prior, et al.
Heart, Lung & Circulation|April 14, 2020
Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and ChallengesJames Anderson, Melanie Lavender, Edmund Lau, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Expert Review of Respiratory Medicine|September 26, 2018
Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practiceMelanie Lavender, Karen Sw Chia, Nathan Dwyer, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Rheumatology (Oxford, England)|October 16, 2012
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Nicole Goh, Tamera Corte, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Pulmonary Circulation|June 10, 2026
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX StudyMandana Nikpour, Alicia Calderone, Susanna M Proudman, et al.
BMJ Open|December 10, 2016
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolAlicia Calderone, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|June 14, 2012
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyVivek Thakkar, Wendy M Stevens, David Prior, et al.
Heart, Lung & Circulation|April 14, 2020
Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and ChallengesJames Anderson, Melanie Lavender, Edmund Lau, et al.
Pageof 3